Strong Results from PRIME Study
The PRIME study, conducted at 19 locations with 5,018 patients, showed a 25% reduction in neonatal mortality and morbidity index, an 18% reduction in neonatal length of hospital stay, and a 20% reduction in NICU admissions.
Successful Fundraising and Strong Balance Sheet
The company successfully raised $57.5 million in a public follow-on offering, securing a cash runway through 2028, with cash, cash equivalents, and available-for-sale securities at $68.2 million as of December 31, 2024.
Expansion Plans and New Board Appointment
Plans to expand commercialization efforts in the US and explore international expansion, particularly in the European Union. Appointment of Jeff Elliott to the Board of Directors, bringing expertise from the medical diagnostics industry.
Focus on Medicaid and Public Health Partnerships
Targeting states with high preterm birth rates for Medicaid partnerships to demonstrate cost savings and impact, with specific focus on Nevada and Louisiana.